Physician profile
Robert G Durrans
NPI 1447332465
$3,799.52
in general payments reported to CMS, 2019-2025
34 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $475 · 2021: $894 · 2022: $671 · 2023: $690 · 2024: $421 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.65 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.03 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $355.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $318.21 | 2019-2025 | Farxiga |
| Allergan, INC. | $219.85 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.41 | 2019-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $207.57 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $141.45 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Corium, LLC | $139.76 | 2023-2025 | Azstarys |
| Abbott Laboratories | $114.25 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $97.68 | 2019-2024 | |
| Alfasigma USA, INC. | $83.55 | 2020-2021 | |
| Novo Nordisk INC | $78.68 | 2020-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $62.65 | 2022 | |
| Axsome Therapeutics, INC. | $55.09 | 2024-2025 | Sunosi, Auvelity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $45.46 | 2022-2023 | Quviviq |
| Zyla Life Sciences, INC. | $40.11 | 2019-2020 | |
| Lundbeck LLC | $32.69 | 2023-2025 | Vyepti |
| Biomerieux INC | $31.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Kowa Pharmaceuticals America, INC. | $28.12 | 2022-2023 | Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $27.12 | 2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $26.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.29 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.68 | 2019 | |
| Shield Therapeutics INC | $19.93 | 2025 | |
| Medtronic, INC. | $19.48 | 2023 | Intellis Adaptivestim |
| Acella Pharmaceuticals, LLC | $18.12 | 2025 | NP Thyroid 60 |
| Amarin Pharma, INC. | $17.21 | 2019 | |
| Almatica Pharma LLC | $16.30 | 2023 | Loreev Xr, Sertraline Hcl |
| Mckesson Medical-Surgical, INC. | $16.04 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.46 | 2023 | Qelbree |
| Eisai INC. | $12.92 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Durrans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.